APA (7th ed.) Citation

HJ, v. d. H., AT, G., MED, C., ECW, B., S, Z., IS, N., . . . T, M. (2021). Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood advances, 5(8), 2165. https://doi.org/10.1182/bloodadvances.2020003731

Chicago Style (17th ed.) Citation

HJ, van der Horst, Gelderloos AT, Chamuleau MED, Breij ECW, Zweegman S, Nijhof IS, Overdijk MB, and Mutis T. "Potent Preclinical Activity of HexaBody-DR5/DR5 in Relapsed And/or Refractory Multiple Myeloma." Blood Advances 5, no. 8 (2021): 2165. https://doi.org/10.1182/bloodadvances.2020003731.

MLA (9th ed.) Citation

HJ, van der Horst, et al. "Potent Preclinical Activity of HexaBody-DR5/DR5 in Relapsed And/or Refractory Multiple Myeloma." Blood Advances, vol. 5, no. 8, 2021, p. 2165, https://doi.org/10.1182/bloodadvances.2020003731.